Drug interactions
Bazedoxifene-conjugated estrogens + Fosaprepitant
Severity: Minor
Bazedoxifene-conjugated estrogens and Fosaprepitant: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Aprepitant is a moderate CYP3A4 inhibitor, but after single-dose fosaprepitant the effect is short lived. Any rise in estrogen or bazedoxifene exposure is likely small and transient.
What this interaction means in plain words
Bazedoxifene-conjugated estrogens and Fosaprepitant have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Bazedoxifene-conjugated estrogens belongs to Endocrine; Fosaprepitant belongs to Gastrointestinal Tract.
Why it happens
Temporary inhibition of CYP3A4 reduces clearance of the hormone components.
What to do
No dose adjustment is needed. Monitor for estrogenic adverse effects if repeated chemotherapy cycles are given.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Bazedoxifene-conjugated estrogens and Fosaprepitant, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Bazedoxifene-conjugated estrogens
- Anastrozole + Bazedoxifene-conjugated estrogens Contraindicated
- Bazedoxifene-conjugated estrogens + Ospemifene Contraindicated
- Antithrombin alfa + Bazedoxifene-conjugated estrogens Major
- Antithrombin iii + Bazedoxifene-conjugated estrogens Major
- Bazedoxifene-conjugated estrogens + Bemiparin Major
- Bazedoxifene-conjugated estrogens + Carbamazepine Major
Other interactions of Fosaprepitant
- Flibanserin + Fosaprepitant Contraindicated
- Fosaprepitant + Pimozide Contraindicated
- Alprazolam + Fosaprepitant Moderate
- Amiodarone + Fosaprepitant Moderate
- Amobarbital + Fosaprepitant Moderate
- Apalutamide + Fosaprepitant Moderate
Frequently asked questions
Can I take Bazedoxifene-conjugated estrogens with Fosaprepitant?
MediHelp rates the interaction as minor. Bazedoxifene-conjugated estrogens and Fosaprepitant have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Aprepitant is a moderate CYP3A4 inhibitor, but after single-dose fosaprepitant the effect is short lived. Any rise in estrogen or bazedoxifene exposure is likely small and transient.
How serious is the interaction between Bazedoxifene-conjugated estrogens and Fosaprepitant?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose adjustment is needed. Monitor for estrogenic adverse effects if repeated chemotherapy cycles are given.
What other medicines interact with Bazedoxifene-conjugated estrogens?
MediHelp also lists interactions of Bazedoxifene-conjugated estrogens with, for example, Anastrozole, Ospemifene, Antithrombin alfa. The full list is on the Bazedoxifene-conjugated estrogens page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
